

# Na Yao

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9855644/publications.pdf>

Version: 2024-02-01

8  
papers

46  
citations

1937457

4  
h-index

2053595

5  
g-index

10  
all docs

10  
docs citations

10  
times ranked

59  
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous hematopoietic stem cell transplantation may improve long-term outcomes in patients with newly diagnosed extranodal natural killer/T-cell lymphoma, nasal type: a retrospective controlled study in a single center. <i>International Journal of Hematology</i> , 2018, 107, 98-104.	0.7	16
2	Using etoposide+â€‰dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis. <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, 863-869.	1.2	10
3	An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment. <i>Journal of Immunology Research</i> , 2021, 2021, 1-26.	0.9	9
4	Long-term outcomes of patients treated with an EPOCHL regimen as first-line chemotherapy for newly diagnosed extranodal natural killer/T-cell lymphoma: a retrospective single-center study. <i>Leukemia and Lymphoma</i> , 2020, 61, 337-343.	0.6	7
5	Outcomes of patients treated with SVILE <i>vs</i>. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study. <i>Cancer Biology and Medicine</i> , 2020, 17, 795-804.	1.4	2
6	Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis. <i>Leukemia and Lymphoma</i> , 2020, 61, 2962-2968.	0.6	1
7	SVILE regimen, a combination of dexamethasone, vindesine, ifosfamide, pegaspargase, and etoposide, for treating relapsed/refractory extranodal natural killer/T-cell lymphoma, nasal type. <i>Leukemia Research</i> , 2020, 96, 106422.	0.4	1
8	Stemness Signature Defined By Logistic Regression Machine Learning and Artificial Intelligence Predicts Outcomes in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2020, 136, 19-20.	0.6	0